[Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients].

Wang XH, Han LN, Yu YR, Wang C, Wang B, Wen XR, Huang H, Jing XC

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition1 Jul 2015Cited by 5 (Europe PMC)

PMID26480664PepBankPUB-26480664

Publisher pageAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In diabetes, post-treatment endothelium-dependent vasodilatation was higher with exenatide than insulin, both with metformin.
In plain wordsIn diabetes, blood vessel widening after treatment was greater with exenatide than insulin, both with metformin.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePost-treatment endothelium-dependent vasodilatation
Study
n = 27
Comparator
Insulin with background metformin
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
A higher level of post-treatment EDV was found in patients in the GLP-1 group compared with those in the insulin group.
1 context sentence(design, population, supporting numbers)
Summary · context
27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group. Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride. Patients in the insulin group were given insulin and metformin hydrochloride.
Report a problemFND-2648066410
02HumanRandomized controlled trialEfficacy outcome
In diabetes, early diastolic mitral annular velocity improved after exenatide treatment with background metformin.
In plain wordsIn diabetes, early heart relaxation velocity improved after exenatide treatment with metformin.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedEarly diastolic mitral annular velocity
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Patients in the GLP-1 group showed improved e, e/a ratio, and E/e ratio after treatments (P 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group. Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride. Patients in the insulin group were given insulin and metformin hydrochloride.
Report a problemFND-2648066403
03HumanRandomized controlled trialEfficacy outcome
In diabetes, the e/a ratio improved after exenatide treatment with background metformin.
In plain wordsIn diabetes, the heart relaxation measure e/a improved after exenatide treatment with metformin.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportede/a ratio
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Patients in the GLP-1 group showed improved e, e/a ratio, and E/e ratio after treatments (P 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group. Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride. Patients in the insulin group were given insulin and metformin hydrochloride.
Report a problemFND-2648066404
04HumanRandomized controlled trialEfficacy outcome
In diabetes, the E/e ratio improved after exenatide treatment with background metformin.
In plain wordsIn diabetes, the heart filling measure E/e improved after exenatide treatment with metformin.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedE/e ratio
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Patients in the GLP-1 group showed improved e, e/a ratio, and E/e ratio after treatments (P 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group. Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride. Patients in the insulin group were given insulin and metformin hydrochloride.
Report a problemFND-2648066405
05HumanRandomized controlled trialEfficacy outcome
In diabetes, mitral E-wave did not change significantly after exenatide treatment with background metformin.
In plain wordsIn diabetes, the heart filling E-wave did not change significantly after exenatide treatment with metformin.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeMitral E-wave
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Patients in the GLP-1 group showed improved e, e/a ratio, and E/e ratio after treatments (P 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group. Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride. Patients in the insulin group were given insulin and metformin hydrochloride.
Report a problemFND-2648066406
06HumanRandomized controlled trialEfficacy outcome
In diabetes, mitral A-wave did not change significantly after exenatide treatment with background metformin.
In plain wordsIn diabetes, the heart filling A-wave did not change significantly after exenatide treatment with metformin.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeMitral A-wave
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Patients in the GLP-1 group showed improved e, e/a ratio, and E/e ratio after treatments (P 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group. Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride. Patients in the insulin group were given insulin and metformin hydrochloride.
Report a problemFND-2648066407
07HumanRandomized controlled trialEfficacy outcome
In diabetes, the E/A ratio did not change significantly after exenatide treatment with background metformin.
In plain wordsIn diabetes, the heart filling E/A ratio did not change significantly after exenatide treatment with metformin.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeE/A ratio
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Patients in the GLP-1 group showed improved e, e/a ratio, and E/e ratio after treatments (P 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group. Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride. Patients in the insulin group were given insulin and metformin hydrochloride.
Report a problemFND-2648066408

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

08HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In diabetes, fasting glucose decreased after treatment in both the exenatide and insulin groups receiving metformin.
In plain wordsIn diabetes, fasting blood sugar decreased in both exenatide and insulin groups receiving metformin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting blood glucose
Study
n = 27
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The levels of FBG and HbA1c decreased significantly in both groups after treatments (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group. Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride. Patients in the insulin group were given insulin and metformin hydrochloride.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2648066401
09HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In diabetes, HbA1c decreased after treatment in both the exenatide and insulin groups receiving metformin.
In plain wordsIn diabetes, HbA1c decreased in both exenatide and insulin groups receiving metformin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c
Study
n = 27
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The levels of FBG and HbA1c decreased significantly in both groups after treatments (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group. Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride. Patients in the insulin group were given insulin and metformin hydrochloride.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2648066402
10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In diabetes, endothelium-dependent vasodilatation increased after treatment in both exenatide and insulin groups receiving metformin.
In plain wordsIn diabetes, blood vessel widening improved in both exenatide and insulin groups receiving metformin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseEndothelium-dependent vasodilatation change
Study
n = 27
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
EDV increased significantly after treatments in both groups (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group. Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride. Patients in the insulin group were given insulin and metformin hydrochloride.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2648066409
11HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In diabetes, endothelium-independent vasodilatation did not change significantly in either exenatide or insulin groups receiving metformin.
In plain wordsIn diabetes, endothelium-independent blood vessel widening did not change significantly in either exenatide or insulin groups receiving metformin.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeEndothelium-independent vasodilatation
Study
n = 27
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
No significant changes in EIV were found in both groups.
1 context sentence(design, population, supporting numbers)
Summary · context
27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group. Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride. Patients in the insulin group were given insulin and metformin hydrochloride.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2648066411

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.